publication venue for
- Eight-week glecaprevir/pibrentasvir in Canadian hepatitis C virus-infected, treatment-naïve, compensated cirrhotic people: CREST study. 19:361-370. 2024
- Identifying Roadblocks to sUccessful Oncolytic Virotherapy: What are they and how do we Approach Them?. 9:695-697. 2014
- DSRNA and the Innate Antiviral Immune Response. 5:325-341. 2010